This series of ATM makes an important contribution to this subject as patients, surgeons, physicians, oncologists after reading the various articles published in the series will be hugely informed on HITHOC as an adjuvant treatment to cytoreductive surgery of primary and metastatic thoracic cancers such as mesothelioma, M1a-pleural effusion lung cancer, advanced thymomas and metastatic cancers.
Present and future of hyperthermic intrathoracic chemotherapy (HITHOC) in thoracic surgical oncology
Assessment of concentration and penetration depth of cisplatin in human lung tissue after decortication and hyperthermic exposure
Hyperthermic intrathoracic chemotherapy (HITHOC): narrative review of the current literature, recommendations and future studies
Perioperative anaesthetic management of patients undergoing thoracic cytoreductive surgery and HITHOC
Hypertermic Intrathoracic Chemotherapy (HITHOC) for thymoma: a narrative review on indications and results
New horizons in non-small-cell lung cancer patients with ipsilateral pleural dissemination (M1a): review of the literature
The series “Hyperthermic Intraoperative Chemotherapy (HITHOC) in Thoracic Surgical Oncology” was commissioned by the editorial office, Annals of Translational Medicine without any sponsorship or funding. Marcello Migliore served as the unpaid Guest Editor for the series.